Wensheng Fan

Dallas’ Spectral AI Appoints Its CFO as CEO and Board Member; Expands GC Role

by | Mar 1, 2024

Dallas-based Spectral AI Inc. has named current chief financial officer Peter M. Carlson as its new chief executive officer.

Spectral AI, the artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatments in wound care, said Carlson succeeds Co-Founder Wensheng Fan as CEO.

After 14 years with Spectral AI, including nearly four as CEO, Fan is transitioning to chief innovation strategist and senior adviser to the CEO. ...

MORE
Spectral AI Names Former Top MiMedx Financial Exec as CFO
by | Dec 27, 2023

Seasoned financial executive Peter M. Carlson has been hired as chief financial officer of Dallas-based Spectral AI Inc., an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care....

MORE
Spectral AI Appoints Chairman of Board’s Executive Committee
by | Dec 1, 2023

Dallas-based predictive artificial intelligence company Spectral AI Inc. announced that Erich Spangenberg has been appointed to the company’s board of directors and named chairman of its executive committee.

Spectral AI focuses on medical diagnostics for faster and more accurate treatment decisions in clinical wound care.

“We are pleased to welcome the return of Erich to the board of directors, where his experience, insights and network will be an invaluable resource for our company,” Spectral AI CEO Wensheng Fan said in a statement....

MORE
Spectral MD Awarded BARDA Project BioShield Contract Worth Up to $149M
by | Sep 28, 2023
The contract is for the advanced development of Spectral MD's DeepView System, an AI-driven burn wound imaging device designed to be used at emergency departments, trauma centers, and burn centers.
MORE

Dallas-Based Spectral MD to List on Nasdaq Via SPAC Merger, Operate as Spectral AI

by | Apr 12, 2023
Spectral MD Holdings, founded over a decade ago, is a predictive analytics company focused on wound care treatment. It plans to delist from the AIM market and list on Nasdaq via a SPAC merger, operating as Spectral AI. The company’s AI-enabled FDA Breakthrough Designated DeepView platform uses AI algorithms and "difficult-to-duplicate" imaging technology to provide healing assessments.
MORE